Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The company’s earnings surpassed estimates in each of the trailing four ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

FRANKFURT, Jan 31 (Reuters) - Novartis (NOVN.S), opens new tab on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings (excluding one-time charges) of $1.98 per share easily beat the Zacks ...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

The transaction is expected to close in the first half of 2025. Also Read: Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries The transaction aligns with ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Novartis shares jumped 3.6% to a three-month high of 97.15 francs at 0941 GMT, with investors also encouraged by the company's upbeat 2025 earnings projections. News Today's news ...

Also Read: AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings? Core operating income was $4.9 billion, up 29% at constant currency, mainly driven by higher net sales. The core ...